113 related articles for article (PubMed ID: 17419282)
1. Expression of MMP-9 and TIMP-1 as prognostic markers in gastric carcinoma.
de Mingo M; Morán A; Sánchez-Pernaute A; Iniesta P; Díez-Valladares L; Pérez-Aguirre E; de Juan C; García-Aranda C; Díaz-López A; García-Botella A; Martín-Antona E; Benito M; Torres A; Balibrea JL
Hepatogastroenterology; 2007; 54(73):315-9. PubMed ID: 17419282
[TBL] [Abstract][Full Text] [Related]
2. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.
Ylisirniö S; Höyhtyä M; Mäkitaro R; Pääakkö P; Risteli J; Kinnula VL; Turpeenniemi-Hujanen T; Jukkola A
Clin Cancer Res; 2001 Jun; 7(6):1633-7. PubMed ID: 11410500
[TBL] [Abstract][Full Text] [Related]
4. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
Wang CS; Wu TL; Tsao KC; Sun CF
Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
[TBL] [Abstract][Full Text] [Related]
5. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
[TBL] [Abstract][Full Text] [Related]
6. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.
Wu CY; Wu MS; Chiang EP; Chen YJ; Chen CJ; Chi NH; Shih YT; Chen GH; Lin JT
Clin Cancer Res; 2007 Apr; 13(7):2054-60. PubMed ID: 17404086
[TBL] [Abstract][Full Text] [Related]
7. Relationship between biomarker expression and allelic alteration in esophageal carcinoma.
Vegh I; Santiuste AD; Colina F; Bor L; Bermejo C; Aragón A; Morán-Jiménez MJ; Gómez-Cámara A; De Salamanca RE; Moreno-González E
J Gastroenterol Hepatol; 2007 Dec; 22(12):2303-9. PubMed ID: 18031395
[TBL] [Abstract][Full Text] [Related]
8. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
Unsal D; Akyurek N; Uner A; Erpolat OP; Han U; Akmansu M; Mentes BB; Dursun A
Am J Clin Oncol; 2008 Feb; 31(1):55-63. PubMed ID: 18376229
[TBL] [Abstract][Full Text] [Related]
9. Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review.
Grunnet M; Mau-Sørensen M; Brünner N
Scand J Gastroenterol; 2013 Aug; 48(8):899-905. PubMed ID: 23834019
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression.
O'Grady A; Dunne C; O'Kelly P; Murphy GM; Leader M; Kay E
Histopathology; 2007 Dec; 51(6):793-804. PubMed ID: 18042068
[TBL] [Abstract][Full Text] [Related]
11. Expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in tissues with a diagnosis of childhood lymphoma.
Bozkurt C; Ertem U; Oksal A; Sahin G; Yüksek N; Birgen D
Pediatr Hematol Oncol; 2008 Sep; 25(7):621-9. PubMed ID: 18850474
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples.
Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R
Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas.
Zheng HC; Takahashi H; Li XH; Hara T; Masuda S; Guan YF; Takano Y
Hum Pathol; 2008 Jul; 39(7):1042-9. PubMed ID: 18482745
[TBL] [Abstract][Full Text] [Related]
14. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300
[TBL] [Abstract][Full Text] [Related]
15. [Tissue inhibitor of metalloproteinase-1 (TIMP-1) in colorectal cancer: correlation with clinico-morphological factors].
Korotkova EA; Gershteĭn ES; Prorokov VV; Kushlinskiĭ NE
Vopr Onkol; 2009; 55(2):171-6. PubMed ID: 19514370
[TBL] [Abstract][Full Text] [Related]
16. Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung.
Takemoto N; Tada M; Hida Y; Asano T; Cheng S; Kuramae T; Hamada J; Miyamoto M; Kondo S; Moriuchi T
Lung Cancer; 2007 Dec; 58(3):376-83. PubMed ID: 17714826
[TBL] [Abstract][Full Text] [Related]
17. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer.
Sørensen NM; Schrohl AS; Jensen V; Christensen IJ; Nielsen HJ; Brünner N
Scand J Gastroenterol; 2008; 43(2):186-91. PubMed ID: 18224564
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significance of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in peripheral blood of patients with gastric carcinoma].
Yoshikawa T; Suzuki K; Kobayashi O; Sairenji M; Motohashi H; Yanoma S; Noguchi Y; Tsuburaya A
Gan To Kagaku Ryoho; 1998 Jul; 25(9):1461-4. PubMed ID: 9703854
[TBL] [Abstract][Full Text] [Related]
19. Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression.
Hornebeck W; Lambert E; Petitfrère E; Bernard P
Biochimie; 2005; 87(3-4):377-83. PubMed ID: 15781325
[TBL] [Abstract][Full Text] [Related]
20. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
